3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
4
Thyroid Carcinoma, Anaplastic
2
Thyroid cancer, follicular
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Heterotaxy Syndrome
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
Cisplatin
4
pembrolizumab
3
selpercatinib
2
pralsetinib
2
Pemetrexed
2
Paclitaxel
2
Fulvestrant
2
Carboplatin
2
trametinib
1
ribociclib
1
repotrectinib
1
patritumab
1
palbociclib
1
golotimod
1
exemestane
1
dabrafenib
1
cobimetinib
1
alectinib
1
abemaciclib
1
Vemurafenib
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiotherapy, Intensity-Modulated
1
Nimorazole
1
Metformin
1
Letrozole
1
Imlunestrant
1
Gemcitabine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Vemurafenib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled